

**Remarks**

Reconsideration of this Application is respectfully requested.


Upon entry of the foregoing amendment, claims 77-246 are pending in the application, with claims 77, 122, and 166 being the independent claims. New claims 205-246 have been added. Support for the new claims can be found throughout the specification. For the Examiner's convenience, **Table 1** (attached) sets out examples of locations where support for the new claims can be found in the present application. (Applicants will provide examples of locations where support may be found in priority Application No. 08/027,146, at a later time if the Examiner so wishes.) These changes are believed to introduce no new matter, and their entry is respectfully requested.

New claims 233-246 read on the provisionally elected species.

Prompt and favorable consideration of this Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473


Date: 11/16/00

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

**Version with markings to show changes made**

***In the Claims:***

Claims 205-246 are newly added.



**Table 1 – Examples of Support for Claims**

**Claim Language**

**Specification**

Method of inducing a CTL response

Page 54, line 31-page 59, line 9

Method of diagnosing or prognosing HCV infection

Page 40, line 30-page 41, line 19

Direct cytotoxicity

Page 39, lines 22-24

Proliferation, lymphokine secretion, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT

Page 39, lines 22-24

Page 40, lines 5-16

Method of determining susceptibility to therapy

Page 41, lines 20-27

T helper peptide

Page 52, line 12-page 54, line 29

Spacer

Page 54, lines 18-29

Carrier

Page 43, lines 4-21

Lipid

Page 43, lines 19-21

Fusion protein

Page 43, lines 4-6

Page 43, 31-34

Page 51, line 12-page 52, line 29

Liposome

Page 58, lines 3-19

Pharmaceutically acceptable carrier

Page 12, lines 23-24

Page 43, lines 12-21

One or more second peptides

Page 38, lines 8-9

Page 43, lines 3-6

Page 43, lines 31-34

Linker

Page 52, lines 31-32

RECEIVED

MAY 15 2000

TECH CENTER 4000 2000